35 results on '"Feagan, B. G."'
Search Results
2. Review article: dose optimisation of infliximab for acute severe ulcerative colitis
3. Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
4. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
5. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
6. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohnʼs disease
7. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
8. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohnʼs disease
9. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohnʼs disease activity
10. Letter: limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohnʼs disease – authorsʼ reply
11. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohnʼs disease
12. Review article: a clinicianʼs guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
13. Evaluation of a daily practice composite score for the assessment of Crohnʼs disease: the treatment impact of certolizumab pegol
14. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab
15. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohnʼs disease in the PRECiSE 2 study
16. Medical management of mild to moderate Crohnʼs disease: evidence-based treatment algorithms for induction and maintenance of remission
17. CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohnʼs disease: a randomized, double-blind, placebo-controlled trial
18. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohnʼs disease
19. Mild to moderate Crohnʼs disease – defining the basis for a new treatment algorithm
20. Systematic review: the effectiveness of budesonide therapy for Crohnʼs disease
21. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease
22. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease
23. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
24. Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE-HSS)-an important first step. Authors’ reply
25. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
26. Reliability of histologic assessment in patients with eosinophilic oesophagitis
27. Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
28. The development of a magnetic resonance imaging index for fistulising Crohn's disease
29. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
30. Editorial: the impact of the placebo effect in Crohn's disease - author's reply
31. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease
32. Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
33. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis
34. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
35. Review article: Drug development in inflammatory bowel disease: budesonide—a model of targeted therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.